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Abstract
Acute hemorrhagic leukoencephalitis is a fulminant demyelinating disease and commonly considered as a rare and
severe variant of acute disseminated encephalomyelitis. Here, we report the clinical, magnetic resonance imaging,
and brain biopsy findings of a 35-year-old female with relapsing-remitting multiple sclerosis, who developed acute
hemorrhagic leukoencephalitis. Magnetic resonance imaging revealed symmetrical hemorrhagic lesions in the basal
ganglia including the thalami. Disease progression was consistent with acute hemorrhagic leukoencephalitis with
rapid deterioration of consciousness and seizures. Besides hemorrhage, infiltration of neutrophils was detected in
brain biopsy.
Acute hemorrhagic leukoencephalitis, also known as Weston-Hurst syndrome, is an excessive immunological
response of unknown etiology. So far, an association with multiple sclerosis has not been reported. The present
case raises the question, whether acute hemorrhagic leukoencephalitis is a specific hyperacute form of acute
disseminated encephalomyelitis, a severe and unspecific form of an immune response in the central nervous
system, or belongs to the spectrum of tumefactive multiple sclerosis.
Keywords: Fulminant demyelinating disease, Multiple sclerosis, Acute hemorrhagic leukoencephalitis, Weston-Hurst
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Introduction
Acute hemorrhagic leukoencephalitis (AHLE) was first
described by Weston Hurst in 1941. It is commonly con-
sidered as a rare and severe variant of acute disseminated
encephalomyelitis (ADEM) and represents a rather ful-
minant course of this disease [1]. AHLE is characterized
by an acute onset and rapidly progressive inflammation
with symmetrical, multifocal brain lesions associated with
acute edematous necrosis and hemorrhage. This rare
disease typically affects young adults and is often associ-
ated with preceding (1–4 weeks) respiratory tract infec-
tions [1, 2]. Multiple sclerosis (MS) is a chronic disease of
the central nervous system (CNS) whose neuropatho-
logical hallmarks are inflammation and demyelination
leading to axonal degeneration [3]. The evolution of MS
lesions depends upon whether the course of the disease is
relapsing-remitting or chronic [3]. Four different neuro-
pathological patterns of demyelinating lesions have been
reported, but in none of these lesions, hemorrhage due to
microvascular damage or necrosis can be found [3, 4].
Case presentation
A then 21-year-old woman was diagnosed with relapsing-
remitting MS in December 1993 according to the MS
criteria of Poser et al. [5]. In 1996, she was enrolled in a
clinical trial with glatiramer acetate and continued inject-
ing this substance after the trial. After suffering relapses in
1997, 2001, 2004, and 2007, treatment was changed to
interferon β-1a (Rebif® 44 μg three times a week) in April
2007. One month later, she developed numbness on the
left side of her face. Magnetic resonance imaging (MRI)
revealed a small contrast enhancing lesion in the right
paracentral lobule (left-outermost column in Fig. 1a, b).
Overall, the MRI depicted 23 supratentorial and one infra-
tentorial lesion on T2-weighted scans underlining high le-
sion burden (Fig. 1b). A relapse was supposed and
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Fig. 1 Chronological order of MRI scans from May 4th 2007 until August 15th 2014. a Images show normal deep nuclei and some unspecific small
T2-weighted (T2w) hyperintensities. b The cranial T2w sequence depicts the high lesion load accompanied by several black holes in T1-weighted
(T1w) sequences. Left-outermost column a–b. The boxes indicate a small nodular enhancement in the right precentral gyrus underlining
disease progression. c The 2nd exam on May 18th, 2007 reveals the onset of space occupying haemorrhagic changes in the deep nuclei
as well as hemorrhagic subcortical foci; hemorrhages are indicated by unenhanced T1w-hyperintensities. d–e The examinations from May
23rd und June 8th show a slow regression of the oedema and the size of the hemorrhagic areas. At both time points and in addition to
the T1w signal hyperintensities caused by hemorrhagic residua, contrast enhancements can be found at the outer rim of the lesions. f By
August 15th, 2014, only parenchymal defects are remaining together with distinctive brain volume loss leading to enlargement of ventricles. g Axial
fluid attenuated inversion recovery imaging (FLAIR) shows an increase in lesions load. Both in the FLAIR and T1w image, confluent and
mainly periventricular located lesions are found. Left-outermost column f–g. Boxes indicate a small enhancing focus in the left frontal
hemisphere evidencing disease activity in multiple sclerosis. Images from May 5th, 2007 are with courtesy of Röntgenpraxis Georgstrasse,
Hannover; images from August 15th, 2014 are with courtesy of Röntgenpraxis Marstall, Hannover. N/A not available
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treatment with prednisolone 100 mg daily was initiated.
High dose i.v. steroid treatment was not desired by the pa-
tient due to travel abroad. In preparation for her travel
(Palma de Mallorca, Spain), she has not undergone any
vaccination. After 4 days of treatment, the patient was ad-
mitted to the hospital while traveling because of progres-
sive disturbance of consciousness.
Following intubation, the patient was transferred to the
intensive care unit. The computed tomography (CT)
showed hypodensities in the basal ganglia, frontal lobe, and
mesencephalon. Internal venous thrombosis was ruled out
by CT venous angiography; MRI revealed symmetrical hy-
perintense lesions in the basal ganglia on T1-weighted and
punctate hemorrhages on T2-weighted images (Fig. 1c).
Cerebrospinal fluid (CSF) analysis showed a normal cell
count with 1 cell/μL and lactate levels within the normal
range. There was an elevated protein indicating a severe
dysfunction of the blood-CSF barrier (total protein 1.2 g/L).
Initially, ceftriaxone, metronidazole, and cotrimoxazole
were given i.v. on suspicion of meningoencephalitis.
The patient developed seizures although MRI re-
examination revealed a slight regression of the lesions in
the basal ganglia (Fig. 1d). EEG showed generalized delta
activity that was consistent with diffuse, severe encephalop-
athy. Chest X-ray and CT scans of the thorax and abdomen
were normal. Serum and hematological laboratory exami-
nations as well as blood cultures yielded unremarkable find-
ings. Immunological parameters (ANA titer, rheumatoid
factor, cyroglobulins) and toxicological screening of the
blood and urine led to inconspicuous findings. Additional
CSF analyses did not reveal evidence for infection with vi-
ruses (HSV, VZV, EBV, and CMV), Borrelia burgdorferi,
syphilis, tuberculosis, Cryptococcus, and toxoplasmosis.
There was no infection with HIV or hepatitis B and C.
Thus, MRI-guided diagnostic brain biopsy of the paren-
chyma was performed. The predominant findings in the
biopsy specimen were perivascular hemorrhagic necrosis
and severe edema of the CNS tissue with an inflammatory
infiltrate principally composed of neutrophils. Some of the
vessels were partially thrombosed (Fig. 2). However, we did
not observe a lymphocytic infiltration, macrophages, or
astrocytic gliosis. Immunohistochemistry was negative for
toxoplasma, HSV-1, HSV-2, EBV (LMP), and CMV. Ther-
apy with intravenous methylprednisolone (1 g daily over
4 days, and then tapering of the dose) followed by intraven-
ous immunoglobulins (30 g daily over 5 days) was initiated
but without any effect. After 1 month, MRI showed a de-
cline of lesion size and edema (Fig. 1e).
Clinically, the subject exhibited a severe spastic tetra-
paresis and was not able to speak. Thus, communica-
tion was only possibly using eye blinks or movements.
Moreover, she experienced aching and rigidity in the
extremities precipitated by tactile stimulation suggest-
ing an abnormality in the long-latency stretch reflexes.
The patient remained in this clinical state and had a
stable clinical course on this poor level without a MS-
specific therapy the following 7 years. In August 2014,
the patient experienced a relapse that led to inter-
nuclear ophthalmoplegia. The most recent MRI exam-
ination displayed a new lesion located paramedian in
the medulla oblongata explaining the disorder of conju-
gate lateral gaze. Moreover, we detected in the left
frontal hemisphere a juxtacortically located small lesion
with contrast uptake as well as a further one in the area
of the middle cerebellar pedicle affecting both sides but
without contrast uptake (left-outermost column in
Fig. 1f, g; images that display the cerebellar pedicles are
not shown). Intravenous methylprednisolone therapy
(1 g daily over 5 days) led to a considerable improve-
ment of the lateral gaze already at day 4 of administra-
tion. Taking the high EDSS of 9.5 into consideration,
disease-modifying therapy was not initiated.
Fig. 2 Hematoxylin and eosin staining. a Severe edema and various fresh bleedings predominately surround capillaries and small arterial vessels.
b Neutrophilic infiltrates were found in some areas. The CNS tissue itself appeared necrotic. c Some smaller vessels exhibited a partial thrombosis
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Discussion
The present case demonstrates an unusual presentation
during a classical course of MS leading to the diagnosis
of AHLE. Diagnosis was provided by MRI findings
showing symmetrical lesions of the basal ganglia and
thalamus, histopathological analyses of affected tissue,
and the rapid clinical deterioration.
AHLE, also known as Weston-Hurst disease, is charac-
terized by acute and rapidly progressive inflammatory
hemorrhagic demyelination of the white matter. The eti-
ology remains unknown, but cross-reactivity between hu-
man myelin antigens and viral or bacterial antigens is
supposed to induce an excessive immunological response
which causes demyelination [6]. Recently, Pirko et al. dem-
onstrated the first murine model of AHLE by injecting the
VP2121–130 viral capsid of the Theiler’s murine encephalo-
myelitis virus that induces a strong in vivo activation of
CD8+ T cells in C57BL/6 mice leading to the development
of hemorrhagic demyelination within 24 h [7].
Acute necrotizing encephalopathy (ANE) might be an-
other differential diagnosis in this case. It is a new dis-
ease entity proposed by Mizuguchi et al. in 1997 and is
characterized by symmetrical, multifocal lesions, usually
associated with edematous necrosis and hemorrhage,
without inflammatory cells [8]. ANE always affects the
thalami and, thus, causes a rapid disturbance of con-
sciousness [9]. The etiology remains unknown, but a
triggering viral infection is supposed. Point mutations in
the RAN binding protein 2 and ephrin typ-B receptor 2
as a novel autoantigen are reported to be involved in dis-
ease mechanism [9].
The clinical differentiation between AHLE and ANE is
a challenge because both diseases present similar find-
ings on MRI and CSF. In this regard, the diagnostic cri-
teria of ANE, proposed by Neilson et al. in 2010, might
help to discern the appropriate diagnosis [8]. The crucial
difference between ANE and AHLE is the invasion of in-
flammatory cells. In ANE, the pathologic hallmark is the
absence of inflammatory cells, while in AHLE, neutro-
philic infiltrates are detected almost regularly [8].
A literature search for similar cases was performed.
We found a case of a 28-year-old woman who partici-
pated in a placebo-controlled trial of oral fingolimod in
relapsing MS (FREEDOMS trial). She developed hemor-
rhaging focal encephalitis in the left temporoparietal
white matter 7 months after commencing fingolimod
[9]. A markedly increased disease activity was noticed
since this patient developed several new T2 hyperintense
lesions in the short-term disease course, one of which
emerged in the left pulvinar thalami. This patient was di-
agnosed with tumefactive MS, but a brain biopsy was
not performed [9]. In another case, a 40-year-old woman
sustained a hemorrhagic lesion in the left frontal lobe
during natalizumab treatment. The authors considered
this as a secondary hemorrhage in a tumefactive lesion
due to an increased vascular fragility. A biopsy of the le-
sion was not performed [10].
The term tumefactive MS refers to demyelinating le-
sions that are larger than those seen in “typical” MS, have
an accompanying edema, and have mass effect resulting in
symptoms and signs that are atypical for MS. Involvement
of basal ganglia have been reported [11, 12]. In a biopsy
series of 168 cases, Lucchinetti et al. observed hypercellu-
lar lesions with confluent demyelination, abundant foamy
macrophages containing myelin debris, reactive astroglio-
sis, “relative” axonal preservation, and variable perivascu-
lar and parenchymal lymphocytic inflammation [11].
Moreover, astrocytic pleomorphism, astrocytes with frag-
mented nuclear inclusions (Creutzfelt–Peters cells), vari-
able nuclear atypia, a rare mitotic figure, and occasional
necrosis or cystic changes may histologically mimic a
tumor [11]. However, Lucchinetti et al. did not report
about hemorrhage in those lesions. According to the hy-
pothesis forwarded by Kepes, such tumefactive lesions oc-
cupy an intermediate position between MS and ADEM,
suggesting that the occurrence of AHLE in the present
case would support this concept [13]. However, it is im-
portant to mention that before and after the AHLE epi-
sode, the subject had/has a rather “ordinary” MS course
without any tumefactive or hemorrhagic lesions. We be-
lieve that the occurrence of AHLE was a separate event
unrelated to MS.
AHLE and ADEM share many features since both are
commonly preceded by upper respiratory infections or by
HSV, EBV, rubella, measles, mumps, or influenza virus in-
fection or vaccination even though overt symptoms of a
preceding infection could not be found in the present case
[6]. It remains elusive whether ADEM and AHLE may be
part of a spectrum of disease with the same fundamental
process resulting from an autoimmune process triggered
by the prodromal infection, rather than distinct entities.
However, different type of CNS infiltrates, i.e., lympho-
cytes in ADEM and neutrophils in AHLE, do not really
support this idea of spectrum diseases.
In conclusion, the present case illustrates the uncom-
mon presentation of AHLE in a MS patient. The diag-
nostic work-up is challenging, and brain biopsy offers
guidance in the diagnosis of AHLE. The present case
raises the question whether AHLE belongs to the
spectrum of ADEM or displays a severe and discrete
form of an immune response in the CNS.
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